

Sarcoglycosides A – C, New *O*-Glycosylglycerol Derivatives from the South China Sea Soft Coral *Sarcophyton infundibuliforme*

by Liang Li^a), Chang-Yun Wang^{*a}), Chang-Lun Shao^a), Yue-Wei Guo^b), Guo-Qiang Li^a), Xue-Ping Sun^a), Lei Han^a), Hui Huang^c), and Hua-Shi Guan^a)

^a) School of Medicine and Pharmacy, Ocean University of China, Key Laboratory of Marine Drugs, Ministry of Education, Qingdao 266003, P. R. China
(phone: +86-532-82031503; e-mail: changyun@ouc.edu.cn)

^b) State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P. R. China


^c) South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510000, P. R. China

Chemical examination of the soft coral *Sarcophyton infundibuliforme* collected from the South China Sea resulted in the isolation of the three new *O*-glycosylglycerol derivatives sarcoglycosides A – C (**1–3**), together with two known compounds, chimyl alcohol (**4**) and hexadecanol (**5**). Their structures were elucidated by combined spectral and chemical methods. All the compounds showed moderate toxicity to brine shrimps *Artemia salina*.

Introduction. – Soft corals are Coelenterates (class Anthozoa, subclass Octocorallia, order Alcyonacea, family Alcyoniidae) [1]. *Sarcophyton*, one of the most widely distributed genus of soft corals, elaborates a rich harvest of secondary metabolites including sesquiterpenes, diterpenes, and polyhydroxylated steroids [2].

O-Glycosylglycerol derivatives are rare in soft corals. Only few glycosylglyceryl ethers have been reported from the genus of *Sarcophyton* [3], *Sinularia* [4][5], and *Cladiella* [6], all of them possessing a batyl alcohol (= 3-(octadecyloxy)propane-1,2-diol) moiety. As part of an effort to discover bioactive substances from Chinese marine invertebrates [7], we now found that the 95% EtOH extract of the soft coral *Sarcophyton infundibuliforme* from the South China Sea showed lethal activity toward brine shrimps *Artemia salina*. Bioassay-guided isolation of the extracts led to the identification of three new *O*-glycosylglycerol derivatives, designated as sarcoglycosides A – C (**1–3**), together with two known compounds, chimyl alcohol (= 3-(hexadecyloxy)propane-1,2-diol; **4**) and hexadecanol (**5**). The present work deals with the isolation and structure elucidation of the new compounds.

Results and Discussion. – Freshly collected specimens of *S. infundibuliforme* were immediately chilled to -20° and kept frozen until their extraction with 95% EtOH. The EtOH extract was partitioned between AcOEt and H₂O, then between BuOH and H₂O. The BuOH-soluble portion was subjected to column chromatography (CC; silica gel). The fraction showing a strong lethal activity toward brine shrimps *A. salina* was further separated by CC (*Sephadex LH-20*) and reversed-phase CC (silica gel (*ODS*))



into sarcoglycosides A–C (**1**–**3**). The AcOEt-soluble portion was fractionated by similar procedures into chimyl alcohol (**4**) [8][9] and hexadecanol (**5**) [10].

Sarcoglycoside A (**1**) is a white amorphous powder. The molecular formula, $C_{33}H_{54}O_{14}$, indicating seven degrees of unsaturation, was established by positive-mode HR-ESI-MS (m/z 697.3413 ($[M + Na]^+$)). The NMR spectra of **1** revealed two anomeric CH groups ($\delta(C)$ 100.0 and $\delta(H)$ 4.67 ($d, J = 4.1$), and $\delta(C)$ 104.6 and $\delta(H)$ 4.09 ($d, J = 6.5$)), together with nine CH–O and four CH_2O groups ($\delta(C)$ 61.1–73.7 and $\delta(H)$ 3.27–4.04), suggesting the presence of two sugar residues and one glycerol unit. Furthermore, the 1H - and ^{13}C -NMR spectra of **1** showed signals attributable to an acyl group ($\delta(C)$ 173.4), four disubstituted $C=C$ bonds ($\delta(C)$ 127.5–132.1 ($d, 8\text{ C}$) and $\delta(H)$ 5.30–5.40 ($m, 8\text{ H}$)), and a terminal Me group ($\delta(C)$ 14.7 and $\delta(H)$ 0.92 ($t, J = 7.2$)), which formed a long-chain unsaturated fatty acid ester moiety. Extensive interpretation of 2D-NMR spectra ($^1H, ^1H$ -COSY, HMQC, and HMBC) led to the complete assignments of the 1H - and ^{13}C -NMR data of the sugar and the glycerol moieties (Table 1). Furthermore, significant HMBCs (Fig. 1) between $CH_2(1)$ and $C(1')$ indicated that the long-chain unsaturated fatty acyl moiety was linked to $C(1)$.

The above-mentioned structural features of **1** were strongly reminiscent of those of *O*-(galactosylgalactosyl)di-*O*-acylglycerol [11], previously isolated from the cultured marine dinoflagellate *Amphidinium carterae*. In fact, **1** differs from **6** only by the functionality at $C(2)$ which lacks a long-chain unsaturated fatty acyloxy substituent. The loss of the fatty acyl group shifted the signal of $H-C(2)$ significantly upfield from $\delta(H)$ 5.30 to 3.49–3.54. Thus, compound **1** was identified as an *O*-(galactosylgalactosyl)-*O*-acylglycerol.

To confirm the absolute configuration, compound **1** was treated with MeONa/MeOH according to a reported method [11][12], yielding an *O*-(galactosylgalactosyl)glycerol **1a** and a fatty acid methyl ester **1b**. Product **1a** ($[\alpha]_D^{25} = +81.0$ ($c = 0.36, H_2O$)) was identical with the previously reported (2*R*)-3-*O*-(6-*O*- α -D-galactopyranosyl- β -D-galactopyranosyl)glycerol (= (2*R*)-2,3-dihydroxypropyl 6-*O*- α -D-galactopyranosyl- β -D-galactopyranoside) on the basis of a comparison of the optical rotation

Table 1. ^1H - and ^{13}C -NMR Data^{a)} of the Glycerol and Sugar Moieties of **1**. δ in ppm, J in Hz.

	$\delta(\text{H})$	$\delta(\text{C})^{\text{c)}$	HMBC
$\text{CH}_2(1)$	4.04 (<i>dd</i> , $J = 11.1, 4.0, \text{H}_a$), 3.97 (<i>dd</i> , $J = 11.1, 6.2, \text{H}_b$)	66.1 (<i>t</i>)	C(1'), C(3) C(1'), C(3)
H–C(2)	3.49–3.54 (<i>m</i>)	68.0 (<i>d</i>)	
HO–C(2)	4.54 (<i>d</i> , $J = 5.3$)		C(1)
$\text{CH}_2(3)$	3.59–3.64 (<i>m</i> , H_a), 3.50–3.56 (<i>m</i> , H_b)	71.0 (<i>t</i>)	C(1''), C(1) C(1''), C(1)
β -D-Gal:			
H–C(1'')	4.09 (<i>d</i> , $J = 6.5$)	104.6 (<i>d</i>)	C(3), C(3'')
H–C(2'')	3.58–3.62 (<i>m</i>)	71.8 (<i>d</i>)	C(4'')
HO–C(2'')	4.50 (<i>d</i> , $J = 4.1$)		C(1''), C(3'')
H–C(3'')	3.27–3.32 (<i>m</i>)	73.7 (<i>d</i>)	C(1''), C(5'')
HO–C(3'')	4.75 (<i>br. s</i>)		
H–C(4'')	3.79–3.83 (<i>m</i>)	68.6 (<i>d</i>)	C(2''), C(6'')
HO–C(4'')	4.98 (<i>d</i> , $J = 5.6$)		C(5'')
H–C(5'')	3.52–3.57 (<i>m</i>)	73.5 (<i>d</i>)	C(3'')
$\text{CH}_2(6'')$	3.56–3.61 (<i>m</i> , H_a), 3.52–3.56 (<i>m</i> , H_b)	67.1 (<i>t</i>)	C(4'') C(4'')
α -D-Gal:			
H–C(1''')	4.67 (<i>d</i> , $J = 4.1$)	100.0 (<i>d</i>)	C(6'''), C(3''')
H–C(2''')	3.63–3.67 (<i>m</i>)	69.0 (<i>d</i>)	C(4''')
HO–C(2''')	4.39 (<i>d</i> , $J = 5.5$)		C(1''')
H–C(3''')	3.52–3.56 (<i>m</i>)	70.1 (<i>d</i>)	C(1'''), C(5''')
HO–C(3''')	4.90 (<i>br. s</i>)		
H–C(4''')	3.66–3.71 (<i>m</i>)	69.4 (<i>d</i>)	C(2'''), C(6''')
HO–C(4''')	4.38 (<i>br. s</i>)		C(5''')
H–C(5''')	3.58–3.62 (<i>m</i>)	71.1 (<i>d</i>)	C(1'''), C(3''')
$\text{CH}_2(6''')$	3.48–3.53 (<i>m</i> , H_a), 3.40–3.45 (<i>m</i> , H_b)	61.1 (<i>t</i>)	C(4'''), C(5''')
HO–C(6''')	4.59 (<i>d</i> , $J = 6.0$)		C(4''') C(5''')

^{a)} In (D_6)DMSO, referred to the residual DMSO ($\delta(\text{H})$ 2.50, $\delta(\text{C})$ 39.5); at 600 (^1H) and 150 MHz (^{13}C); for the NMR data of the acyl residue, see *Exper. Part.* ^{b)} Assignments by ^1H , ^1H -COSY, HMQC, and HMBC experiments. ^{c)} By DEPT sequence.

($[\alpha]_{\text{D}}^{25} = +83.0$ ($c = 0.50$, H_2O)) and NMR data [11–13]. And **1b** was determined as methyl octadeca-6,9,12,15-tetraenoate by GC/MS analysis. Consequently, the whole structure of sarcoglycoside A was identified as shown in formula **1**.

Sarcoglycoside B (**2**) was obtained as a white amorphous powder, and had the molecular formula $\text{C}_{24}\text{H}_{48}\text{O}_7$, as deduced from its HR-ESI-MS exhibiting a *pseudo*-molecular-ion peak at m/z 471.3307 ($[M + \text{Na}]^+$). Its ESI-MS exhibited a fragment-ion peak at m/z 317 ($[M + \text{H} - 132]^+$) corresponding to the loss of one pentosyl moiety. Analysis of the spectroscopic data of **2** (Table 2) revealed that it was a glycolglyceryl ether. Thus, the ^1H - and ^{13}C -NMR spectra of **2** displayed characteristic signals assignable to a terminal β -D-lyxose moiety at $\delta(\text{C})$ 100.0 (*d*), 70.5 (*d*), 68.8 (*d*), 80.3 (*d*), and 63.3 (*t*), and $\delta(\text{H})$ 5.05 (*d*, $J = 2.2$, H–C(1'')), 3.82–3.87 (*m*, H–C(2'')), 4.01 (*br. s*, H–C(3'')), 3.85–3.89 (*m*, H–C(4'')), 3.95 (*br. d*, $J = 11.9$, H_b –C(5'')), and 3.79 (*br. d*,




Fig. 1. Selected $^1\text{H},^1\text{H}$ -COSY correlations and HMBCs of compound **1**

$J = 11.9$ Hz, $\text{H}_a\text{-C}(5'')$) [14] and a glycerol moiety at $\delta(\text{C})$ 70.2 (*t*), 69.8 (*d*), and 63.6 (*t*), and $\delta(\text{H})$ 3.52 (*d*, $J = 5.4$, $\text{CH}_2(1)$), 3.83–3.87 (*m*, $\text{H-C}(2)$), 3.67 (*dd*, $J = 11.4$, 3.5, $\text{H}_a\text{-C}(3)$), and 3.63 (*dd*, $J = 11.4$, 6.0, $\text{H}_b\text{-C}(3)$) [3]. Furthermore, the ^1H -NMR spectrum of **2** showed a terminal-Me signal at δ 0.87 (*t*, $J = 6.9$, $\text{Me}(16')$), a broad CH_2 *s* at δ 1.26 (26 H, $\text{CH}_2(3')$ to $\text{CH}_2(15')$), a *m* at δ 1.52–1.58 ($\text{CH}_2(2')$), and another *m* at δ 3.40–3.46 ($\text{CH}_2(1')$), all assignable to the long-chain fatty alcohol moiety.

The structure of **2** was established by detailed analysis of the 1D- and 2D-NMR ($^1\text{H},^1\text{H}$ -COSY, HMQC, and HMBC) spectra (Table 2, Fig. 2). In particular, the location of the long-chain fatty alcohol moiety at C(1) and the β -D-lyxose moiety at C(3) was secured by the $^1\text{H},^{13}\text{C}$ -long-range correlations observed in the HMBC spectrum between $\text{CH}_2(1')$ and C(1), and between $\text{H-C}(1'')$ and C(3), respectively. The NOESY correlations $\text{H-C}(1'')/\text{H-C}(2'')$, $\text{H-C}(2'')/\text{H-C}(3'')$, and $\text{H-C}(3'')/\text{H-C}(4'')$ suggested that all these H-atoms are orientated on the same face (α) of the molecule (Fig. 3), confirming the identity of a lyxose unit. Furthermore, the β -orientation of $\text{H-C}(2)$ was also supported by two clear NOE cross-peaks between $\text{H-C}(2)$ and $\text{CH}_2(5'')$ in the NOESY plot (Fig. 3).


The absolute configuration of **2** was determined after acid hydrolysis [3]. From the reaction of **2** with 2M H_2SO_4 , 3-*O*-hexadecyl-*sn*-glycerol and D-lyxose were obtained. The configuration of 3-*O*-hexadecyl-*sn*-glycerol was determined as (*R*) by comparison of its optical rotation ($[\alpha]_{\text{D}}^{25} = +1.2$ ($c = 0.24$, THF)) with those of authentic samples, *i.e.*, 3-*O*-hexadecyl-*sn*-glycerol ($[\alpha]_{\text{D}}^{20} = +2.7$, THF) and 1-*O*-hexadecyl-*sn*-glycerol ($[\alpha]_{\text{D}}^{20} = -2.7$, THF) [15]. Thus, the configuration of C(2) in sarcoglycoside B was deduced as (*S*). In addition, the configuration of the obtained lyxose was determined as D by comparison of its optical rotation ($[\alpha]_{\text{D}}^{25} = -12.4$ ($c = 0.11$, H_2O)) with those of authentic samples, *i.e.*, D-lyxose ($[\alpha]_{\text{D}}^{20} = -14.8$, H_2O) and L-lyxose ($[\alpha]_{\text{D}}^{20} = +13.5$, H_2O) [16]. The D-lyxose was further confirmed by a co-TLC with an authentic sample (PrOH/ H_2O /ammonia 60:30:2.4, R_f 0.55).

Sarcoglycoside C (**3**) was also obtained as a white amorphous powder. Its molecular formula was deduced to be $\text{C}_{24}\text{H}_{48}\text{O}_7$, identical to that of **2**. $^1\text{H},^1\text{H}$ -COSY and HMBC (Table 2, Fig. 2) experiments established the same H-atom sequence and framework as

Table 2. ^1H - (600 MHz) and ^{13}C - (150 MHz) NMR Data^{a)} of **2** and **3**. δ in ppm, J in Hz.

	2		3	
	$\delta(\text{H})$	$\delta(\text{C})^{\text{c}}$	$\delta(\text{H})$	$\delta(\text{C})^{\text{c}}$
$\text{CH}_2(1)$	3.52 (<i>d</i> , $J=5.4$)	70.2 (<i>t</i>)	3.53 (<i>d</i> , $J=5.6$)	69.9 (<i>t</i>)
H–C(2)	3.83–3.87 (<i>m</i>)	69.8 (<i>d</i>)	3.82–3.86 (<i>m</i>)	69.5 (<i>d</i>)
$\text{CH}_2(3)$	3.67 (<i>dd</i> , $J=11.4, 3.5, \text{H}_a$),	63.6 (<i>t</i>)	3.65–3.70 (<i>m</i>),	63.3 (<i>t</i>)
	3.63 (<i>dd</i> , $J=11.4, 6.0, \text{H}_b$)			
$\text{CH}_2(1')$	3.40–3.46 (<i>m</i>)	71.9 (<i>t</i>)	3.40–3.46 (<i>m</i>)	71.8 (<i>t</i>)
$\text{CH}_2(2')$	1.52–1.58 (<i>m</i>)	29.5 (<i>t</i>)	1.52–1.58 (<i>m</i>)	29.5 (<i>t</i>)
$\text{CH}_2(3')$	1.26 (<i>br. s</i>)	32.0 (<i>t</i>)	1.26 (<i>br. s</i>)	31.9 (<i>t</i>)
$\text{CH}_2(4')$ to $\text{CH}_2(13')$	1.26 (<i>br. s</i>)	29.0–30.0 (<i>t</i>)	1.26 (<i>br. s</i>)	29.0–30.0 (<i>t</i>)
$\text{CH}_2(14')$	1.26 (<i>br. s</i>)	26.1 (<i>t</i>)	1.26 (<i>br. s</i>)	26.0 (<i>t</i>)
$\text{CH}_2(15')$	1.26 (<i>br. s</i>)	22.8 (<i>t</i>)	1.26 (<i>br. s</i>)	22.7 (<i>t</i>)
Me(16')	0.87 (<i>t</i> , $J=6.9$)	14.2 (<i>q</i>)	0.87 (<i>t</i> , $J=6.9$)	14.1 (<i>q</i>)
β -D-Lyx:				
H–C(1'')	5.05 (<i>d</i> , $J=2.2$)	100.0 (<i>d</i>)	5.06 (<i>d</i> , $J=2.3$)	99.2 (<i>d</i>)
H–C(2'')	3.82–3.87 (<i>m</i>)	70.5 (<i>d</i>)	3.85–3.91 (<i>m</i>)	70.2 (<i>d</i>)
H–C(3'')	4.01 (<i>br. s</i>)	68.8 (<i>d</i>)	4.00 (<i>br. s</i>)	68.9 (<i>d</i>)
H–C(4'')	3.85–3.89 (<i>m</i>)	80.3 (<i>d</i>)	3.83–3.89 (<i>m</i>)	79.0 (<i>d</i>)
$\text{CH}_2(5'')$	3.79 (<i>br. d</i> , $J=11.9, \text{H}_a$),	63.3 (<i>t</i>)	3.75 (<i>br. d</i> , $J=11.9$),	63.2 (<i>t</i>)
	3.95 (<i>br. d</i> , $J=11.9, \text{H}_b$)			

^{a)} In CDCl_3 , referred to the residual CHCl_3 ($\delta(\text{H})$ 7.26, $\delta(\text{C})$ 77.0). ^{b)} Assignments by ^1H , ^1H -COSY, HMQC, and HMBC experiments. ^{c)} By DEPT sequence.

Fig. 2. ^1H , ^1H -COSY correlations and key HMBCs of compounds **2** and **3**

those of **2**. Careful comparison of the ^1H -NMR data of **3** and **2** revealed differences at C(3) and the sugar moiety. The $\text{CH}_2(3)$ signals of **2** were splitted into two *dd* with distinct coupling constants, $J(\text{H}_a, 2) = 3.5$ Hz and $J(\text{H}_b, 2) = 6.0$ Hz, respectively (Table 2). The $\text{CH}_2(3)$ signals of **3**, however, were splitted into two *m*, of which the coupling constants were unidentified. The $\delta(\text{H})$ values of $\text{CH}_2(5'')$ of the lyxose moiety were particularly diagnostic: δ 3.75 and 3.94 for **3**, and δ 3.79 and 3.95 for **2** due to the spatial interaction with H–C(2). These differences suggested the inversion of the configuration at C(2). α -Orientation of H–C(2) in **3** was further confirmed by the NOESY experiment (Fig. 3), where no cross-peaks H–C(2)/ $\text{CH}_2(5'')$ were observed. Furthermore, following the same method as for **2**, 1-*O*-hexadecyl-*sn*-glycerol and D-lyxose were obtained from **3** with 2M H_2SO_4 . The 1-*O*-hexadecyl-*sn*-glycerol from **3** ($[\alpha]_{\text{D}}^{25} = -1.3$ ($c=0.20$, THF)) differed from the corresponding *O*-hexadecylglycerol




Fig. 3. Key NOESY correlations of compounds **2** and **3**

from **2** only by the sign of the optical rotation. This confirmed that the configuration at C(2) of **3** was (*R*). Thus, sarcoglycoside C was the 2-epimer of sarcoglycoside B.

Compounds **1–3** showed lethality to brine shrimps *A. salina* at a concentration of 50 µg/ml with lethal rates of 78.4, 44.7, and 41.5%, respectively. And the two known compounds, chimyl alcohol (**4**) and hexadecanol (**5**), also exhibited moderate lethal activities toward *A. salina*, with lethal rates of 58.9 and 32.5%, respectively.

It may be worthy to point out that sarcoglycoside A (**1**) is the first glycosylglycerolipid isolated from soft corals. Sarcoglycosides B (**2**) and C (**3**), two glycosylglycerol ethers consisting of a lyxose residue and a chimyl alcohol moiety, are the first example of the co-occurrence of both C(2) epimers of a naturally occurring *O*-glycosylglycerol derivative. In addition, *O*-glycosylglycerol derivatives with lyxose residues are rare in marine materials; to the best of our knowledge, there has been only one analogue isolated before from the same genus of *Sarcophyton* (*S. solidum* [3]). These characters showed that there might be chemotaxonomic relationships between the two species. Furthermore, compounds **2–5** containing the same hexadecanol moiety, suggest that they are probably biogenetically related to each other. The evaluation of their physiological functions in soft coral *S. infundibuliforme* as well as the exploration of their chemoecological roles in the coral-reef ecosystem would be interesting subjects for future investigations.

The research work was financially supported by the *National Natural Science Foundation of China* (Nos. 40776073 and 30572314), the *Cultivation Fund of the Key Scientific and Technical Innovation Project of the Ministry of Education of China* (No. 706038), the *Program for New Century Excellent Talents in Universities of the Ministry of Education of China* (No. NCET-05-0600), the *National High Technology Research and Development Program of China 863 Program Grant* (No. 2007AA091701), and the *Basic Research Program of Science and Technology, Ministry of Science and Technology of China* (No. 2007FY210500).

Experimental Part

General. Column chromatography (CC): commercial silica gel (SiO₂, 200–300 mesh; *Qingdao Haiyang Chemical Group Co.*), octadecylsilyl (ODS) silica gel (*Unicorn*; 45–60 µm), and *Sephadex LH-20* (*Amersham Biosciences*). TLC: precoated SiO₂ plates (*Yantai Zifu Chemical Group Co.*; G60, F₂₅₄).

Optical rotation: *Jasco-P-1020* digital polarimeter. IR Spectra: *Nicolet-Nexus-470* spectrophotometer; $\bar{\nu}$ in cm^{-1} . ^1H - and ^{13}C -NMR Spectra: *Jeol-Eclips-600* spectrometer; at 600 (^1H) and 150 MHz (^{13}C); δ in ppm rel. to Me_4Si as internal standard, J in Hz. ESI- and HR-ESI-MS: *Q-TOF-Ultima-Global-GAA076* LC mass spectrometer; in m/z . GC/MS System: *Agilent-6890* gas chromatograph and *Agilent-5973* mass-selective detector in the EI mode.

Animal Material. Specimen of the soft coral *S. infundibuliforme* were collected from the Wenchang coral reef at a depth of -10 m in the South China Sea, in November 2006 and were frozen immediately after collection. The animal was identified by *H. H.* of the South China Sea Institute of Oceanology, Chinese Academy of Sciences. A voucher sample (No. WCLL-1-4) is available for inspection at the Ocean University of China.

Extraction and Isolation. The frozen specimen (460.0 g, dry weight) were cut into pieces and extracted exhaustively with 95% EtOH (3×1000 ml) at r.t. The EtOH extract was evaporated to give a residue (18.0 g) which was partitioned between AcOEt (3×600 ml) and H_2O (300 ml), and then between BuOH (3×400 ml) and H_2O (300 ml), successively. The BuOH soln. was concentrated to give a dark green residue (4.8 g) which was fractionated by CC (SiO_2 , $0 \rightarrow 100\%$ MeOH/ CHCl_3): *Fractions A–D*. The bioactive *Fr. D* (270.0 mg) was purified by CC (*Sephadex LH-20*, $\text{CHCl}_3/\text{MeOH}$ 1:1) followed by reversed-phase CC (SiO_2 (*ODS*)): **1** (12.0 mg), **2** (6.4 mg), and **3** (10.0 mg). The AcOEt-soluble portion (7.0 g) was separated by CC (SiO_2 , $0 \rightarrow 100\%$ AcOEt/petroleum ether): *Frs. 1–10* (by TLC). *Fr. 7* (268 mg) was subjected to CC (*Sephadex LH-20*, CHCl_3) and further purified by CC (SiO_2 , petroleum ether/acetone 6:1 \rightarrow 7:3): **4** (38.5 mg) and **5** (160.0 mg).

Sarcoglycoside A (= (6*Z*,9*Z*,12*Z*,15*Z*)-Octadeca-6,9,12,15-tetraenoic Acid (2*R*)-3-[(6-*O*- α -galactopyranosyl- β -*D*-galactopyranosyl)oxy]-2-hydroxypropyl Ester; **1**): White amorphous powder. $[\alpha]_D^{25} = +20.8$ ($c = 0.30$, MeOH). IR (KBr): 3350, 2926, 1739, 1693, 1534, 1076, 1023, 678. ^1H -NMR ((D_6) DMSO): 5.30–5.40 (*m*, H–C(6'), H–C(7'), H–C(9'), H–C(10'), H–C(12'), H–C(13'), H–C(15'), H–C(16')); 2.75–2.80 (*m*, 2 H–C(8'), 2 H–C(11'), 2 H–C(14')); 2.31 (*t*, $J = 7.0$, 2 H–C(2')); 2.01–2.06 (*m*, 2 H–C(5'), 2 H–C(17')); 1.50–1.55 (*m*, 2 H–C(3')); 1.31–1.34 (*m*, 2 H–C(4')); 0.92 (*t*, $J = 7.2$, Me(18')). ^{13}C -NMR ((D_6) DMSO): 173.4 (*s*, C(1')); 132.1 (*d*, C(16')); 130.2, 130.1, 128.7, 128.6, 128.5, 128.4 (*6d*, C(6'), C(7'), C(9'), C(10'), C(12'), C(13')); 127.5 (*d*, C(15')); 33.9 (*t*, C(2')); 29.6 (*t*, C(4')); 29.0 (*t*, C(5')); 27.0, 25.8, 25.7 (*3t*, C(8'), C(11'), C(14')); 24.6 (*t*, C(3')); 20.6 (*t*, C(17')); 14.7 (*q*, C(18')). ^1H - and ^{13}C -NMR: *Table 1*. ESI-MS: 697 ($[M + \text{Na}]^+$). HR-ESI-MS: 697.3413 ($[M + \text{Na}]^+$, $\text{C}_{33}\text{H}_{54}\text{NaO}_{14}$; calc. 697.3411).

Sarcoglycoside B (= (2*S*)-3-(Hexadecyloxy)-2-hydroxypropyl β -*D*-Lyxofuranoside; **2**): White amorphous powder. $[\alpha]_D^{25} = -41.2$ ($c = 0.50$, CHCl_3). IR (KBr): 3393, 2920, 2851, 1467, 1143, 1073, 1005. ^1H - and ^{13}C -NMR: *Table 2*. ESI-MS: 919 ($[2M + \text{Na}]^+$), 471 ($[M + \text{Na}]^+$), 449 ($[M + \text{H}]^+$), 317, 299. HR-ESI-MS: 471.3307 ($[M + \text{Na}]^+$, $\text{C}_{24}\text{H}_{48}\text{NaO}_7$; calc. 471.3298).

Sarcoglycoside C (= (2*R*)-3-(Hexadecyloxy)-2-hydroxypropyl β -*D*-Lyxofuranoside; **3**): White amorphous powder. $[\alpha]_D^{25} = -58.5$ ($c = 0.50$, CHCl_3). IR (KBr): 3393, 2920, 2851, 1467, 1143, 1073, 1005. ^1H - and ^{13}C -NMR: *Table 2*. ESI-MS: 471 ($[M + \text{Na}]^+$), 449 ($[M + \text{H}]^+$), 317. HR-ESI-MS: 471.3280 ($[M + \text{Na}]^+$, $\text{C}_{24}\text{H}_{48}\text{NaO}_7$; calc. 471.3298).

Methanolysis of 1. A soln. of **1** (7.5 mg) in anhyd. MeOH (1.5 ml) was treated with 3% MeONa/MeOH (1.5 ml), and the mixture was stirred at r.t. for 1.5 h. The mixture was neutralized with positive-ion-exchange resin and filtered, and the filtrate partitioned between CH_2Cl_2 and H_2O . Evaporation of the solvent from the CH_2Cl_2 phase yielded fatty acid methyl ester **1b** (2.3 mg), which was identified by GC/MS to be methyl octadeca-6,9,12,15-tetraenoate. The aq. phase was concentrated to give a residue, which was purified by CC (*Sephadex LH-20*): (2*R*)-2,3-dihydroxypropyl 6-*O*- α -*D*-galactopyranosyl- β -*D*-galactopyranoside (**1**; 3.6 mg).

Acid Hydrolysis of 2 and 3. A soln. of **2** (6 mg) in MeOH (1 ml) was added to 2*M* H_2SO_4 (1 ml) and kept for 4 h at 105° in a sealed ampule. The mixture was dried under N_2 to remove MeOH and then diluted with H_2O (3.5 ml) and extracted with CH_2Cl_2 (3×7 ml). The org. layer was washed with H_2O , dried (Na_2SO_4), and concentrated to give a white amorphous powder, which was identified as 3-*O*-hexadecyl-*sn*-glycerol (= (2*R*)-3-(hexadecyloxy)propane-1,2-diol; 2.4 mg). The aq. phase was neutralized with BaCO_3 , filtered, and concentrated to give a residue which was purified by CC (*Sephadex LH-20*, MeOH) to furnish *D*-lyxose (1.1 mg).

By the same hydrolysis procedure, compound **3** yielded *1-O-hexadecyl-sn-glycerol* (= (2S)-3-(hexadecyloxy)propane-1,2-diol; 2.0 mg) and D-lyxose (1.0 mg).

Bioassays. The brine-shrimp lethality assay was performed on *A. salina* according to standard protocols [17][18].

REFERENCES

- [1] B. F. Bowden, J. C. Coll, S. J. Mitchell, J. Mulder, G. J. Stokie, *Aust. J. Chem.* **1978**, *31*, 2049.
- [2] J. W. Blunt, B. R. Copp, W.-P. Hu, M. H. G. Munro, P. T. Northcote, M. P. Prinsep, *Nat. Prod. Rep.* **2009**, *26*, 170.
- [3] M. Zhang, K.-H. Long, *Nat. Prod. Res. Dev.* **1995**, *7*, 12.
- [4] C. Subrahmanyam, R. Kulatheeswaran, *Indian J. Chem., Sect. B* **1999**, *38*, 1388.
- [5] V. Anjaneyulu, P. V. Subba Rao, P. Radhika, H. Laatsch, L. N. Misra, *Indian J. Chem., Sect. B* **2000**, *39*, 121.
- [6] V. Anjaneyulu, P. V. Subba Rao, P. Radhika, H. Laatsch, R. N. Asolkar, *Indian J. Chem., Sect. B* **2001**, *40*, 405.
- [7] L. Li, C.-Y. Wang, H. Huang, E. Mollo, G. Cimino, Y.-W. Guo, *Helv. Chim. Acta* **2008**, *91*, 111.
- [8] L.-Y. Liang, S.-Z. Deng, Q. Zhang, D.-J. Xiao, H.-M. Wu, *Chin. J. Mar. Drugs* **2001**, *6*.
- [9] C. Subrahmanyam, C. V. R. V. Anjaneyulu, P. Satyanarayana, P. V. Subba Rao, *Tetrahedron* **1992**, *48*, 3111.
- [10] W. Zhang, H.-X. Lou, G.-Y. Li, H.-M. Wu, *J. Asian Nat. Prod. Res.* **2003**, *5*, 189.
- [11] J. Wu, L.-J. Long, Y.-S. Song, S. Zhang, Q.-X. Li, J.-S. Huang, Z.-H. Xiao, *Chem. Pharm. Bull.* **2005**, *53*, 330.
- [12] M. Kobayashi, K. Hayashi, K. Kawazoe, I. Kitagawa, *Chem. Pharm. Bull.* **1992**, *40*, 1404.
- [13] P. Baruah, N. C. Baruah, R. P. Sharma, J. N. Baruah, P. Kulanthaivel, W. Herz, *Phytochemistry* **1983**, *22*, 1741.
- [14] R. G. S. Ritchie, N. Cyr, B. Korsch, H. J. Koch, A. S. Perlin, *Can. J. Chem.* **1975**, *53*, 1424.
- [15] S. D. Stamatov, J. Stawinski, *Tetrahedron Lett.* **2005**, *46*, 1601.
- [16] S. H. Bhuiyan, Z. Ahmed, M. Utamura, K. Izumori, *J. Ferment. Bioeng.* **1998**, *86*, 513.
- [17] P. N. Solis, C. W. Wright, M. M. Anderson, M. P. Gupta, J. D. Phillipson, *Planta Med.* **1993**, *59*, 250.
- [18] B. N. Meyer, N. R. Ferrigni, J. E. Putnam, L. B. Jacobson, D. E. Nicols, J. L. Mclaughlin, *Planta Med.* **1982**, *45*, 31.

Received January 26, 2009